Carla M.L. van Herpen

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.6K citations · Full text

Medicine, Pathology, Head And Neck Cancer +5

Pan-cancer whole-genome analyses of metastatic solid tumours

Peter Priestley, Jonathan Baber, Martijn P. Lolkema et al. · Nature · 2019 · 1.1K citations · Full text

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

Paolo A. Ascierto, Dirk Schadendorf, Carola Berking et al. · The Lancet Oncology · 2013 · 638 citations

Tumor Biology, Open-label Phase 2, Medicine +12

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

Udai Banerji, Carla M.L. van Herpen, Cristina Saura et al. · The Lancet Oncology · 2019 · 549 citations · Full text

Breast Oncology, Her2-expressing Breast Cancer, Medicine +9

Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

J.S.W. Stewart, Ezra E.W. Cohen, Lisa Licitra et al. · Journal of Clinical Oncology · 2009 · 379 citations